Contraindications
None.
Special warnings
Vaccinate healthy animals only.
Special precautions for use
Special precautions for safe use in the target species:
De-worming at least 10 days prior to vaccination is recommended.
Only feline leukaemia virus (FeLV) negative cats should be vaccinated. Therefore, a test for presence of FeLV before vaccination is recommended.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Adverse events
Cats:
Common (1 to 10 animals / 100 animals treated): | Injection site reaction1, Injection site swelling1 Injection site oedema1, Injection site nodule1 Hyperthermia2,3, Apathy3 Digestive tract disorder3 |
Rare (1 to 10 animals / 10,000 animals treated): | Injection site pain4,5 Sneezing5 Conjunctivitis5 |
Very rare (<1 animal / 10,000 animals treated, including isolated reports): | Anaphylaxis6 |
1 A moderate and transient local reaction (<2 cm) is observed after the first injection and resolves spontaneously within 3 to 4 weeks at the most. After the second injection, and subsequent administrations, this reaction is markedly reduced.
2 Lasting 1 to 4 days.
3 Transient signs.
4 At palpation.
5 This resolves without any treatment.
6 In case of anaphylactic shock, appropriate symptomatic treatment should be administered.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
Use during pregnancy, lactation or lay
Pregnancy and lactation:
Do not use in pregnant cats.
The use is not recommended during lactation.
Interaction with other medicinal products and other forms of interaction
Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with FELIGEN CRP or FELIGEN RCP. No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after another veterinary medicinal product therefore needs to be made on a case by case basis.
Symptoms of overdose (and where applicable, emergency procedures and antidotes)
No adverse reactions were observed after an overdose administration (2 doses) of the veterinary medicinal product other than those mentioned in section 'adverse reactions' except local reactions that can last longer (from 5 to 6 weeks at the most).